Newsfiscal.ai
Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of REYOBIQ™ at SNO 2026
· Published
Article summary
Cerenome, Inc. announced that interim data from its ongoing ReSPECT-LMM multidose study of REYOBIQ™ will be presented at the Society for Neuro-Oncology (SNO) 31st Annual Meeting.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…